Trial Profile

Phase 3 trial of Ixo-vec for Age-Related Macular Degeneration

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions; Registrational
Acronyms AQUARIUS

Most Recent Events

18 Apr 2025 New trial record
15 Apr 2025 According to Adverum Biotechnologies media release,the company plans to Initiate the global AQUARIUS Phase 3 trial in 2H 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com